State Street Corp Sage Therapeutics, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,926,239 shares of SAGE stock, worth $15.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,926,239

Previous 2,474,862 18.24%

Holding current value

$15.9 Million

Previous $26.9 Million 21.5%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.02 - $13.08 $3.17 Million - $5.9 Million	451,377 Added 18.24%	2,926,239 $21.1 Million
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $21.4 Million - $36.2 Million	-2,019,934 Reduced 44.94%	2,474,862 $26.9 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $10.7 Million - $15.5 Million	576,574 Added 14.72%	4,494,796 $84.2 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $7.87 Million - $10.2 Million	-460,245 Reduced 10.51%	3,918,222 $84.9 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $34.8 Million - $102 Million	2,079,327 Added 90.44%	4,378,467 $90.1 Million
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $17.7 Million - $25.9 Million	-435,233 Reduced 15.92%	2,299,140 $108 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $263,759 - $329,575	7,077 Added 0.26%	2,734,373 $115 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $7.32 Million - $9.92 Million	-227,387 Reduced 7.7%	2,727,296 $104 Million
Q3 2022 Nov 15, 2022	BUY	$32.28 - $43.27 $665,581 - $892,184	20,619 Added 0.7%	2,954,683 $116 Million
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $2.72 Million - $3.75 Million	98,708 Added 3.48%	2,934,064 $94.8 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $20.5 Million - $30.5 Million	666,826 Added 30.75%	2,835,356 $93.9 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $7.14 Million - $9.07 Million	192,578 Added 9.75%	2,168,530 $92.2 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $25.7 Million - $36.7 Million	639,194 Added 47.82%	1,975,952 $87.6 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $4.36 Million - $6.29 Million	79,368 Added 6.31%	1,336,758 $75.9 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $19.5 Million - $26.7 Million	-275,489 Reduced 17.97%	1,257,390 $94.1 Million
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $2.6 Million - $3.96 Million	44,480 Added 2.99%	1,532,879 $133 Million
Q3 2020 Nov 10, 2020	SELL	$41.13 - $62.45 $25.9 Million - $39.3 Million	-628,937 Reduced 29.7%	1,488,399 $91 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $11.2 Million - $18.6 Million	432,202 Added 25.65%	2,117,336 $88 Million
Q1 2020 May 11, 2020	BUY	$26.15 - $77.24 $44.1 Million - $130 Million	1,685,134 New	1,685,134 $48.4 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Sage Therapeutics, Inc. Transaction History